Pharmaceutical

Simcere Zaiming and TargetRx agree TGRX-326 commercial rights

Simcere Zaiming has entered a collaboration deal with Shenzhen TargetRx to bring TGRX-326 to the Chinese market.

Sep 4, 2024 - 04:00
Simcere Zaiming and TargetRx agree TGRX-326 commercial rights
Simcere Zaiming has entered a collaboration deal with Shenzhen TargetRx to bring TGRX-326 to the Chinese market.
Read the original article

Tags:

Previous Article

UK NHS launches vaccine programme for RSV

Next Article

Why the Importer of Record (IoR) is vital in the clinical supply chain ­­

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines

STAT+: FDA issues warning to wholesaler sued by Gilead ...

Jun 28, 2023

ARTBIO divulges plans for proprietary isotope manufacturing technology

ARTBIO divulges plans for proprietary isotope manufactu...

Dec 28, 2023

FDA fast tracks Mendus’s acute myeloid leukaemia vaccine vividencel

FDA fast tracks Mendus’s acute myeloid leukaemia vaccin...

Sep 9, 2023